Researchers link schizophrenia risk to 641 additional genes

Large-scale gene network study expands the genetic map of schizophrenia

Researchers at the Lieber Institute for Brain Development and collaborators from the University of Bari and more than 60 psychiatric hospitals report that they have identified 641 previously unrecognized genes associated with schizophrenia. The result comes from a new computational framework designed to capture long-range regulatory relationships among genes, rather than focusing only on DNA variants located close to a gene.

The study, published in Nature Genetics, analyzed genetic data from more than 102,000 individuals and brain tissue samples from hundreds of donors across six brain regions. Its central claim is that schizophrenia genetics cannot be understood adequately by looking only at nearby genetic signals. Instead, distant variants can influence disease risk through wider networks of coordinated gene activity in the brain.

Why the finding matters

Schizophrenia has long been known to run in families, but translating that inherited risk into a clear set of biological mechanisms has been difficult. Many studies have identified genomic regions associated with the disorder, yet moving from those regions to the specific genes and pathways involved has remained a major bottleneck.

The new work addresses that problem by treating gene regulation less like an isolated one-to-one map and more like a network. In that framework, a disease-associated variant may exert influence far from its physical location through co-expression relationships and regulatory links. By modeling those longer-distance interactions, the team says it was able to recover hundreds of genes that conventional approaches would have missed.

That is an important shift because psychiatric disorders are widely understood to be polygenic and biologically distributed. A method that can trace how many small effects combine across networks may offer a more realistic picture than one centered only on the closest gene to a particular variant.

Moving beyond the nearest gene

According to the source text, traditional methods generally examine variants in the immediate proximity of genes under study, even though researchers recognize that much of a gene’s involvement in disease may depend on long-distance variants. The new modeling approach attempts to bridge that gap by incorporating gene co-expression networks.

Senior author Dr. Giulio Pergola described the limitation of older strategies as searching “under the lamppost,” where the light is easiest rather than where the full biology is actually visible. The network framework, by contrast, is meant to illuminate a broader neighborhood of interactions.

That conceptual change has practical consequences. If schizophrenia risk is spread across interconnected pathways, then understanding the disorder requires identifying not only individual genes but also the architecture that links them. The study’s 641 newly implicated genes represent a substantial expansion of that architecture.

What pathways came into focus

The findings point to biological pathways involved in glutamate signaling, communication between brain cells, immune processes, and synaptic function. Those categories align with several long-running hypotheses in schizophrenia research, especially the idea that the disorder reflects disruptions in how neural circuits develop, communicate, and adapt over time.

Glutamate signaling is particularly notable because it has often been discussed as a candidate mechanism in schizophrenia, distinct from but intersecting with better-known dopamine-centered explanations. Synaptic and cell-communication pathways also fit with the view that schizophrenia is less a problem in one single brain region than a systems-level disorder affecting how networks of neurons coordinate.

The immune signal is also significant, though it should be interpreted carefully. Immune-related associations in psychiatric genetics do not by themselves establish a simple inflammatory cause. What they do suggest is that the boundary between brain biology and broader regulatory systems may be more intertwined than earlier models allowed.

Scale and methodology

One reason the study stands out is its scale. More than 102,000 individuals were included in the genetic analysis, alongside postmortem brain tissue from hundreds of donors covering six brain regions. That combination of population genetics and brain-specific expression data is important because schizophrenia-associated variants often have subtle effects that only become interpretable when linked to actual tissue-level biology.

The study’s strength, as described in the source material, lies in integrating those data layers instead of treating them separately. Large sample sizes improve statistical power, while cross-region brain tissue helps reveal whether identified networks are plausible in the organ most directly relevant to the disease.

Even so, gene discovery does not immediately translate into clinical tools. Association studies identify candidates and pathways, not simple diagnostic markers or near-term cures. The more realistic value is that a richer map of schizophrenia biology can improve target selection for future experiments and potentially guide the development of therapies that are more biologically grounded.

What this changes for the field

The study strengthens a broader movement in psychiatric genomics away from single-gene narratives and toward network biology. That shift has implications for how researchers design experiments, interpret risk, and prioritize drug development. If risk emerges from distributed regulatory systems, then interventions may need to address pathways or circuit-level effects rather than isolated molecular targets.

It also suggests that some past genetic studies may have been directionally correct but incomplete. Important signals were present, yet the tools used to interpret them were too narrow to capture long-range interactions. In that sense, the new paper is not only about adding 641 genes. It is about expanding the rules for how schizophrenia genetics is read.

The next step

The immediate challenge will be validation and functional follow-up. Researchers will need to test how these newly implicated genes behave in cellular and animal models, whether they converge on specific developmental windows, and which of them are most central within the identified networks. Not every associated gene will carry equal biological weight.

Still, the scale of the result is hard to ignore. By combining a large genetic cohort with a network-based view of gene regulation in the brain, the team has materially broadened the known landscape of schizophrenia risk. For a disorder that has resisted simple explanations for decades, that is a meaningful advance: not a final answer, but a much more detailed map of where the answers may lie.

This article is based on reporting by Medical Xpress. Read the original article.